Colorectal Adenocarcinoma

P=N/A, N=50, Recruiting, Centre Paul Strauss | Trial completion date: Sep 2026 --> Jul 2030

Notably, elevated miR-501 expression was associated with more than a twofold increased risk of death in stage IV CRC patients from the TCGA-COAD cohort. IL-17 signaling may drive CRC progression and poor clinical outcomes in part through the induction of miR-501-5p, underscoring its potential role in immune-related cancer metastasis and as a prognostic biomarker.

Moreover, MALINC1 knockdown enhanced the sensitivity of these cells to platinum-based drugs. These findings suggest that a prognostic model based on six key disulfidptosis-related lncRNAs holds potential for predicting outcomes in patients with COAD, and that targeting MALINC1 may offer new insights into colorectal cancer chemotherapy.

Exogenous ACSL3 expression rescued the tumor-suppressive effects caused by YTHDF1 silencing. YTHDF1 enhances ACSL3 translation in an m6A-dependent manner to promote lipid metabolism, thereby facilitating the progression of READ.

We present a 57-year-old man with KRAS G13D-mutant, liver-dominant metastatic rectal adenocarcinoma and recurrent fluoropyrimidine-associated coronary vasospasm precluding 5-fluorouracil and capecitabine. After multimodal first-line therapy and regorafenib, trifluridine/tipiracil (TAS-102) plus bevacizumab was initiated and integrated with liver-directed treatments for oligoprogressive disease. This combined strategy achieved approximately 16.6 months of disease control, substantially exceeding the median progression-free survival reported in the SUNLIGHT trial, with manageable hematological toxicity and preserved performance status. This case highlights the value of TAS-102 plus bevacizumab combined with focal liver-directed therapy as a feasible long-term strategy for selected patients with oligoprogressive mCRC when fluoropyrimidines cannot be used.

Important limitations, mainly sensitivity values need to be addressed. Further analyses are needed in order to position this technique in the routine clinical practice.

P1, N=300, Enrolling by invitation, M.D. Anderson Cancer Center | Recruiting --> Enrolling by invitation

P=N/A, N=4186, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Apr 2026

Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.

The minimally invasive anatomical approach allowed precise vascular control and achievement of oncologically adequate margins in a technically demanding central segment. Larger clinical series are needed to define optimal management strategies and long-term oncologic outcomes in this setting.

In conclusion, this study provides a comprehensive pan-cancer characterization of CHRNA7, offering novel insights into its potential role as a prognostic biomarker and immunotherapeutic target. These findings could facilitate the development of personalized cancer treatment strategies customized according to the expression level and functional status of CHRNA7.

Notably, 7-methoxyheptaphylline markedly suppressed STAT3 phosphorylation in a concentration-dependent manner, comparable to the STAT3 inhibitor JSI-124...Collectively, our results demonstrate that C. harmandiana exerts broad-spectrum anticancer activity through coordinated modulation of the JNK-STAT3 axis, leading to caspase-dependent apoptosis. These findings highlight its potential as a promising candidate for the development of STAT3-targeted anticancer therapies.